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Accumulating mutations may drive cells into the acquisition of abnormal phenotypes
that are characteristic of cancer cells. Cancer cells feature profound alterations in pro-
liferation programs that result in a new population of cells that overrides normal tissue
construction and maintenance programs. To achieve this goal, cancer cells are endowed
with up regulated survival signaling pathways. They also must counteract the cytotoxic
effects of high levels of nitric oxide (NO) and of reactive oxygen species (ROS), which are
by products of cancer cell growth. Accumulating experimental evidence associates can-
cer cell survival with their capacity to up-regulate antioxidant systems. Elevated
expression of the antioxidant protein thioredoxin-1 (Trx1) has been correlated with
cancer development. Trx1 has been characterized as a multifunctional protein, playing
different roles in different cell compartments. Trx1 migrates to the nucleus in cells
exposed to nitrosative/oxidative stress conditions. Trx1 nuclear migration has been
related to the activation of transcription factors associated with cell survival and cell
proliferation. There is a direct association between the p21Ras-ERK1/2 MAP Kinases
survival signaling pathway and Trx1 nuclear migration under nitrosative stress. The
expression of the cytoplasmic protein, the thioredoxin-interacting protein (Txnip), de-
termines the change in Trx1 cellular compartmentalization. The anti-apoptotic actions of
Trx1 and its denitrosylase activity occur in the cytoplasm and serve as important regu-
lators of cell survival. Within this context, this review focuses on the participation of Trx1
in cells under nitrosative/oxidative stress in survival signaling pathways associated with
cancer development.y School of Medicine, New York, NY, USA.
(A. Stern).
g Gung University.
ublishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
s/by-nc-nd/4.0/).
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system
Cytosolic thioredoxin-1 (Trx1) andmitochondrial thioredoxin-
2 (Trx2) are 12 kDa multi-functional proteins with two
conserved Cys residues (Cys32 and Cys35 for Trx1 and Cys31
and Cys34 for Trx2) at their redox active site. They play a
major role in cellular redox balance and signaling in normal
cells and tumor cells [1e5]. Thioredoxins are expressed in
prokaryotic and eukaryotic cells and apparently are present in
all living cells [1,6].
Trx1 and Trx2 (Trxs) are part of the Trx system, a major
antioxidant system which is essential for maintenance of the
intracellular redox status. The Trx system is formed by the
Trxs, NADPH and the Trx reductases (TrxR). Mammalian
TrxRs are selenoenzymes that operate as pyridine nucleotide
disulfide oxidoreductases [5,7,8]. They maintain Trxs in their
reduced state due to the presence of a selenocysteine residue
in the active site of TrxRs [9], TrxRs are highly reactive pro-
teins which consume NADPH and reduce the disulfide form of
Trxs to a dithiol [Fig. 1].
TrxRs comprise a group of three isoenzymes, the cytosolic
TrxR1 [10,11], the mitochondrial TrxR2 [12,13], and the testis
specific Trx glutathione reductase [14] . Expression and sub-
cellular localization of the different members of the Trx sys-
tem expands the number of their targets. Direct targets such
as peroxiredoxins, which are essential for reduction of H2O2
and organic peroxides associated with intracellular redox
signaling require disulfide reduction by Trx1 or Trx2 for their
function [5]. Ribonucleotide reductase activity as an indirect
target of the Trx system is of major importance for the supply
of DNA precursors. The enzyme which is up regulated in
tumor cells uses Trx1 as an electron donor for deoxy-
ribonucleotide and DNA synthesis [2,5,15]. Elevated expres-
sion of TrxR1 is found in human and murine tumor cell lines
[2,3,16,17]. P53 mutations in glioblastomas are associatedFig. 1 The Trx system and its redox couples: *TrxRSSe/TrxR/SHSe
reducing equivalents fromNADPH and are essential for denitrosyl
Selenylsulfide.with increased expression of TrxRs and this expression is
used for tumor grading in astrocytomas [18]. Inhibition of
expression of TrxR1 in a mouse model of prostate cancer and
in human hepatocellular carcinoma SMMC-7721 cells causes
growth inhibition in both situations [19,20].
In the absence of TrxRs, alternative pathways may be
operative in maintaining intracellular redox status. The
methionine sulfoxide pathway may be a possible alternative
pathway. After generation of null-hepatocytes for both TrxR
and GSH reductase genes in transgenic mice, though they
were long-term viable, these mice were dependent on
methionine supplementation in their diets needed for de novo
synthesis of cysteine and GSH [21]. There are other reductases
capable of redox-regulation of the system, but themethionine
sulfoxide pathway is responsible for maintaining the redox
environment when NADPH does not deliver the reducing
power either to Trx or to GSH [22e24].
Among the Trxs the best characterized is Trx1 [5]. It regu-
lates the activity of various signaling proteins and antioxidant
enzymes within cells. Trx1 also acts as a positive regulator of
survival related signaling pathways to enhance survival of
tumor cells [25,26]. Trx1 provides reducing equivalents to
peroxiredoxins that in turn will reduce reactive oxygen spe-
cies (ROS) [5], and directly inhibits pro apoptotic proteins such
as the apoptosis signal-regulating kinase 1 (ASK-1) [27]. The
intracellular location of Trx1 is a determining factor for its
function as a mediator of signaling events occurring either in
the cytoplasm or in the nucleus.
Trx1 plays a central role in signaling associated with the
Trx system in normal and tumor cell development. This oc-
curs in the regulation of a large number of transcription fac-
tors that are redox sensitive [28e34], the interaction with
partners of components of the system, e.g. the Thioredoxin
interacting protein e Txnip [35,36] and the metabolism of low
molecular weight S-nitrosothiols (SNO) [37e45]. All have in
common the central role played by Trx1.and TrxSS/Trx(SH)2 are responsible for the delivery of
ase activities. *SHSe stands for Selenothiol and SSe stands for
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role of the Trx system in tumor development. The reader is
referred to other review and research articles to access this
information [2,3,25,26]. This review focuses on Trx1 intracel-
lular compartmentalization under nitrosative/oxidative stress
and its consequences on survival signaling pathways associ-
ated with tumor progression.Thioredoxin-1 signaling and cellular
compartmentalization
Signaling pathways are operative through reversible post-
translational modifications of proteins and their intracellular
localization. This is true for Trx1, which is predominantly a
cytosolic protein that can be secreted from cells in two forms,
a full-length and a truncated form [46]. In the extracellular
milieu, both forms perform co-cytokine and chemokine ac-
tivities [47e49]. Cytosolic Trx1 participates in anti-apoptotic
signaling events related to the inhibition of the pro apoptotic
protein kinase ASK-1 [27], while Trx1 migration from the
cytosol to the nucleus is involved in signaling associated with
cell survival, even though it does not have a nuclear locali-
zation sequence [48]. A number of different oxidative stress
inducing agents such as H2O2, UV irradiation, and the
chemotherapeutic agent cis-Diamine-dichloroplatinum (II)
induce Trx1 nuclear migration. Intracellular generation or
exposure of cells to NO also promotes Trx1 nuclear trans-
location [31,48,49].
DNA binding activity of a number of transcription factors,
including NFkB, AP-1, p53, and the glucocorticoid receptor (GR)
[28e32] is regulated by Trx1 reducing activities of essential
cysteine residues. Trx1-mediated reduction of Cys62 located
in the DNA binding loop of the p50 subunit of NFkB facilitates
its transcriptional activities [33]. Trx1, in association with
reducing catalyst redox-factor-1 reduces conserved cysteine
residues within the DNA-binding domains of Fos and Jun,
promoting the transcriptional activity of AP-1 [29]. P53 tran-
scriptional activity relies on Trx1-mediated redox regulation
of a conserved DNA-binding domain that contains a zinc ion
and essential cysteine residues [31].
Glucocorticoid receptor (GR), a ligand-inducible transcrip-
tion factor, has its activity regulated by Trx1. Essential
conserved cysteine residues at the DNA-binding domain and
the ligand binding domain of GR are targets for Trx1 mediated
redox regulation of GR. Trx1 preserves ligand binding activity
of cytosolic GR [34] and promotes GR nuclear translocation
and its DNA binding activity [32].Thioredoxin-1, nitrosative/oxidative stress, and
survival signaling
Endogenous NO production is derived from the oxidation of L-
arginine catalyzed by the three NO synthases isoforms. An
inducible isoform (iNOS) and two constitutive isoforms iso-
lated initially in endothelial cells (eNOS) and in neuronal cells
(nNOS) are well characterized [50]. The three isoforms are
expressed in a variety of tumor cells [47,48,51,52].Nerve growth factor (NGF) stimulation of nNOS in rat
pheochromocytoma PC12 cells raises intracellular NO levels,
which promotes cell differentiation and survival accompanied
by Trx1 nuclear migration. Inhibition of phosphorylation of
the ERK1/2 MAP Kinases by the MEK inhibitor PD98059,
prevents NGF/NO-induced Trx1 nuclear migration and de-
creases cell survival [49]. NO-mediated activation of p21Ras
upstream to the ERK1/2 MAP Kinases is essential for neuronal
survival [53].
A connection has been found between Trx1 nuclear
migration, the p21Ras-ERK1/2 MAP Kinases signaling
pathway, and signaling events related to cell survival under
nitrosative stress conditions. Trx1 migrates to the nucleus in
HeLa cells in the presence of increasing concentrations of an
external source of NO, the low molecular weight SNO, s-
nitroso-N-acetyl-penicillamine (SNAP) [48]. The nuclear
migration occurs at SNAP concentrations that cause nitro-
sylation and activation of p21Ras, with downstream activa-
tion of the ERK1/2 MAP Kinases. This results in cell survival,
while inhibition of the pathway results in apoptotic cell death.
The participation of a major partner of Trx1 in the cytosol, the
Thioredoxin-interacting protein (Txnip) is essential to the
overall process [36]. Txnip expression levels are up regulated
by increasing vitamin D3 levels. Its original namewas Vitamin
D(3)-Up-Regulated Protein-1 (VDUP-1) [54]. Txnip binds
exclusively to the reduced form of Trx1 in vitro and in vivo. The
catalytic center of Trx1 is important for the interaction of Trx1
and Txnip, since mutation of the two redox active cysteine
residues and their substitution by serine residues prevents the
interaction [35]. Txnip has been characterized as a negative
regulator of the Trx1-mediated pro-survival signaling path-
ways in tumor tissue and tumor cell models [55].
Rat cardiomyocytes and rat pulmonary smooth muscle
cells exposed to oxidative or nitrosative stress by using either
H2O2 or S-nitrosoglutathione (GSNO), undergo down regula-
tion of Txnip expression [56,57]. Down regulation of Txnip
expression and activation of the ERK1/2 MAP Kinases in HeLa
cells incubated with SNAP or H2O2 results in ERK1/2 MAP Ki-
nases and Trx1 migration to the nucleus [36]. Incubation of
HeLa cells withMEK inhibitors or the ectopic expression of the
ERK1/2 MAP kinases cytoplasmic anchor, PEA-15 (the 15 Kda
phosphoprotein enriched in astrocytes), originally identified
in astrocytes [58] and now identified in a variety of human and
mouse tissues [59,60].
PEA-15 inhibits the integrin-stimulated p21Ras/ERK1/2
MAP kinases signaling axis [61]. PEA-15 participates in a wide
range of cellular processes including, glucosemetabolism, cell
proliferation and apoptosis. PEA-15 is regulated by the PKC-
dependent phosphorylation of Ser104 and by Calcium
Calmodulin-Kinase-II or Akt-dependent phosphorylation of
Ser116 [57,62e64]. Phosphorylation of PEA-15 determines its
stability and its cellular compartmentalization. Non-
phosphorylated PEA-15 binds to the ERK1/2 MAP Kinases
anchoring these kinases in the cytoplasm [65].
The ectopic expression of PEA-15 prevents nuclear migra-
tion of Trx1 and down regulation of Txnip expression levels
[36]. Over expression of Txnip inhibits Trx1 nuclear migration
under nitrosative/oxidative stress, whereas Txnip mRNA
silencing facilitates Trx1 nuclear migration even in the
absence of stress conditions. These findings indicate that
Fig. 2 The Trx1/p21Ras-ERK1/2 MAP kinases/PEA-15/Txnip compartmentalized signaling pathway is stimulated by nitrosative/
oxidative stress and is associated with tumor development. (A) The Ras-Raf-MEK-ERK1/2 signaling axis is activated under
nitrosative oxidative stress. Under these conditions expression of Akt is up regulated and expression of Txnip is down-
regulated. Trx1 and the ERK1/2 MAP kinases migrate to the nuclear compartment. (B) Nuclear translocation of Trx1 and the
ERK1/2 MAP kinases is prevented in three situations: (1) Cells pre-incubated with the MEK inhibitor PD98059; (2) Cells over-
expressing the cytoplasmic anchor of ERK1/2 MAP kinases e PEA-15; (3) Cells over-expressing Txnip.
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ERK1/2 MAP kinases and down regulation of the expression
levels of Txnip, associated with stimulation of Trx1 nuclear
migration under nitrosative/oxidative stress conditions al-
lows for cell survival [36]. These observations are summarized
in [Fig. 2].
Trx1 compartmentalization, Txnip expression levels and
cancer development
Oxidants inhibit the expression levels of Txnip [36,56,57].
Oxidative stress-induced knock down of Txnip expression
facilitates Trx1 nuclear migration [36]. Txnip is down regu-
lated in tumor cells which have high intracellular ROS levels.
This is associated with the development of cancer [66].
Hypermethylation of the Txnip promoter associated with
oxidative stress-induced renal carcinogenesis results in loss
or decrease of Txnip levels [67]. Histone deacetylation medi-
ates the repression of Txnip expression. The use of two his-
tone deacetylase inhibitors, suberoylanilide hydroxamic acid
e SAHA and depsipeptide - FK228, stimulate Txnip expression
resulting in a decrease of Trx1 expression in cancer cells but
not in normal cells [66].
Tumor stage development is a determining factor for Txnip
expression. Thyroid tumor cells at different stages of devel-
opment exhibit differential Txnip expression [68]. Metastatic
differentiated thyroid cancer cells have high Txnip expression
and anaplastic thyroid cancer cells have low or absent
Txnip expression. It appears that Txnip down regulation is of
major importance in the transition from differentiated to
advanced poorly differentiated and non-differentiated thyroid
cancer [68].
A data compilation on Txnip expression levels in tumor
tissues and cell lines and their correlation with clinical
importance has been done. Down regulation of Txnipexpression is a consistent feature in tumor cell models,
tumor animal models, and in tumor tissues obtained from
patients [55].
In contrast to the various studies involving Txnip expres-
sion and tumor development, only a few studies have dealt
with the signaling events associated with a decrease in Txnip
expression and its consequences on tumor development.
Reduced levels of Txnip in A549 human lung cancer cells and
in MDA-MB-231 triple negative human breast cancer cells
promote the transcriptional activity in response to TGF-b,
enhancing TGF-b-induced Smad2 phosphorylation [69].
Enhanced expression in A549 cells of Snail and Slug tran-
scription factors are associated with TGF-bmediated induc-
tion of the Epithelial-Mesenchymal-Transition (EMT). These
cells show spindle-like morphology and low expression levels
of E-Cadherin. The participation of other elements of the Trx1
compartmentalized survival signaling pathway in addition to
Txnip, such as PEA-15 and the ERK1/2 MAP kinases, are
involved in tumor development. Coordinated signaling events
associated with increased PEA-15 expression or the pharma-
cological inhibition of the ERK1/2 MAP kinases results in the
maintenance of Txnip expression in HeLa cells exposed to
oxidative and nitrosative stress [36]. Regarding tumor devel-
opment, PEA-15 and the ERK1/2 MAP kinases play opposite
roles. Increased activity of the ERK1/2 MAP kinases is found in
a variety of cancers. ERK1/2 MAP kinases-dependent tran-
scription activities in the nucleus downstream of activated
growth factor receptors and p21Ras influence cell survival and
proliferation, two determining factors associated with cancer
progression [70e72]. The presence of elevated PEA-15
expression results in an interaction with the ERK1/2 MAP ki-
nases to prevent the kinases associated nuclear transcription
activity [73,74].
Two hundred fifty two samples of mammary epithelial
tissue from breast cancer and normal subjects evenly divided
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protein is highly expressed in normal mammary epithelial
tissue, and its expression is decreased in tissue obtained from
invasive tumors, suggesting an inverse relationship between
PEA-15 expression and tumor invasion [74]. The effect of PEA-
15 on tumor invasion is related to the anchoring of the ERK1/2
MAP kinases in the cytoplasm, preventing its migration to the
nucleus [74]. Colorectal cancer cells from patients displaying
high PEA-15 expression levels are associated with a better
clinical prognosis [74].
A combination of events involving down regulation of PEA-
15 and/or Txnip expression promotes nuclear migration of
Trx1 and the ERK1/2 MAP kinases. Such conditions are
encountered in tumor cells at an advanced stage with several
lines of evidence converging to suggest that the up regulation
of Trx1 expression is associated with tumor development
[25,36,75e78].
Trx1 and TrxR1 expression levels are up regulated in cells
from breast cancer patients compared to normal individuals
[25]. These findings are indicative of a major role for Trx1 and
the Trx system in compensating for the inhibition of the GSH
antioxidant pathway which is detected in malignant tumors
at an advanced stage [76]. This compensation may be trans-
lated into stimulation of survival signaling pathways related
to enhanced levels of Trx1 in highly aggressive human pros-
tate cancer PC3 cells. Stimulation of PC3 cells with androgen
up regulated Trx1 expression, making the cells less sensitive
to the cytotoxicity of pro-oxidant compounds [77]. Trx1
expression in prostate cancer cell nuclei of patients with high-
grade prostatic adenocarcinoma and metastatic prostatic
adenocarcinoma is high compared with those with low-grade
prostate cancer as identified by nuclear staining for Trx1.
Semi-quantitative analysis of immunohistochemical staining
in human prostate tissue has been correlated with the in-
tensity of nuclear Trx1 staining and prostate cancer progres-
sion [77].
The distribution of TrxR1 and Trx1 into cellular compart-
ments has been correlated with the outcome in 38 patients
with gallbladder carcinoma (GBC). In all samples analyzed,
TrxR1 expression has been detected only in the cytoplasm.
TrxR1 cytoplasmic expression has been detected in the inva-
sion front in 72% of the samples, while Trx1 expression has
been detected in 100% of the samples analyzed, with Trx1
nuclear location in 76% of these samples. Within this group,
Trx1 nuclear expression is observed in the invasion front in
45% of the samples. This suggests that Trx1 nuclear expres-
sion in the invasion front is a significant marker of poor
prognosis in GBC patients [78].
Thioredoxin-1 compartmentalization and survival signaling
Enhanced survival signaling pathways are associated with
tumor development. Trx1 is distributed in the cytoplasm and
in the nucleus upon changes in intracellular redox status,
which is an essential feature of Trx1-mediated survival
signaling. Trx1-mediated survival signaling involves the
redox-mediated activation of the p21Ras-ERK1/2 MAP kinases
signaling axis, the activation of the Akt protein, down regu-
lation of PEA-15, and of Txnip expression [Fig. 2]. This com-
bination of events permits the shift of Trx1 between thecytoplasm, where the protein inhibits apoptotic signaling
pathways, and the nuclear compartment, where Trx1 stimu-
lates cell proliferation promoting the activity of transcription
factors. This has been observed in various tumor cell models,
tumor animal models, and in tumor tissues obtained from
patients, emphasizing the importance of the Trx1/p21Ras-
ERK1/2 MAP kinases/PEA-15/Txnip signaling axis in tumor
development [36].
Being part of an effective antioxidant defense system in
tumor cells, Trx1 has been investigated as a therapeutic
target. 1-methylpropyl 2-imidazolyl disulfide (PX-12) is a
small-molecule inhibitor of Trx1 [79]. The PX-12 mechanism
of action is not completely understood. PX-12 reversibly in-
hibits Trx1 by thioalkylation of Cys32 and Cys35 residues at
the catalytic site [79]. Thioalkylation of Cys73 residue at the
structural site by PX-12 irreversibly inhibits Trx1 [79].
PX-12 also affects cancer cell growth because it is a
competitive inhibitor for TrxR1 in addition to its direct effects
on Trx1 [79]. It also causes GSH depletion and cell cycle arrest
leading to further cell death by apoptosis [80] and inhibits
tubulin polymerization by cysteine oxidation [81].
The use of PX-12 in clinical trials include a phase I trial in
the treatment of gastrointestinal cancer [82], and a phase II
trial in the treatment of advanced pancreatic cancer [83].
Drug-resistant multiple myeloma may be treated with Trx1
inhibitors, including PX-12, which is effective therapeutically
in refractory multiple myeloma [84].Thioredoxin-1-mediated denitrosylation of proteins is
associated with survival signaling
The covalent attachment of NO to the thiol group of a cysteine
is recognized as a redox-based posttranslational modification
known as s-nitrosylation [85]. The direct reaction between NO
and a thiol is very slow and therefore considered biologically
irrelevant. Several mechanisms have been proposed to
circumvent this problem in explaining SNO formation in bio-
logical systems. Mg-mediated catalysis is involved in the re-
action between NO and GSH [86]. The participation of iron
dinitrosyl complexes as precursors in the formation of SNO
under hypoxic conditions, is especially relevant in tumor cells
[87]. Trans-nitrosylation, the transfer of a nitrosomoiety from
one thiol to another can be added to these mechanisms. The
intracellular generation of SNO resulting from trans-
nitrosylation reactions occurs after exposure of cells to
exogenous low-molecular weight SNOs (SNAP, GSNO, and
SNOCys) [37,43,88]. Trans-nitrosylation contributes to target
specificity in s-nitrosylation reactions [89,90].
S-nitrosylation of proteins belonging to the cytoskeletal
organization, cellular metabolism, redox homeostasis and
signal transduction pathways is found in normal and tumor
cells [91,92]. SNOs derived from peptides (GSH) or proteins
might play a major role in human health and disease [93,94].
There are at least 1000 s-nitrosylated mammalian proteins
[91e95]. Among these s-nitrosylated signaling proteins are the
small GTPase p21Ras, EGFR, and Src tyrosine kinases. S-
nitrosylation of these signaling proteins trigger proliferation
and survival signaling pathways in normal and tumor cells
[96e101].
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translate into a pro-oxidant intracellular environment,
accompanied by oxidation of DNA, lipids, and proteins [102].
Protein oxidative modifications mediated by ROS and NO in
normal and tumor cells are reversed by the actions of GSH and
Trx1 [85,103].
GSH and Trx1 reduce sulfenic acids, disulfides, and SNOs
[4]. However, there are important differences regarding the
reducing activities of both reducing agents. GSH is utilized by
glutaredoxin to restore oxidized thiols in proteins [104], while
Trx1 acts directly on the oxidative modifications of proteins
reducing oxidized thiols. Trx1 and glutaredoxin display
different electrostatic affinities for their protein targets
thereby determining different targets for each protein [105].
GSH and Trx1 can mediate denitrosylation of proteins and
peptides reviewed in [42]. GSH-mediated denitrosylation of
intracellular SNOs generate GSNO [85]. GSNO is a major sub-
strate of GSNO reductase, a ubiquitously expressed enzyme in
eukaryotic and prokaryotic organisms [106]. In addition to
GSNO reductase, denitrosylation of GSNO is effectively carried
out by Trx1 [39,43]. Trx1 serves as a denitrosylase, removing
NO from s-nitrosylated cysteine residues of GSNO and
signaling proteins, making it an important line of defense
against nitrosative stress [85,103]. Trx1 also catalyzes the
trans-nitrosylation of its potential targets depending on the
redox state of the dithiol at the active site [107].
Trx1-mediated cytoprotection is related to its deni-
trosylase/transnitrosylase activity. In vitro studies performed
under nitrosative stress conditions demonstrate that Trx1
reduces two critical cysteine residues that are s-nitrosylated
in the transcription factor AP-1, resulting in restoration of its
DNA binding capacity [39,108]. Trx1-mediated denitrosylation
of a specific cysteine residue at the active site of caspase-3
promotes enzyme activity and apoptosis in human lympho-
cytes and endothelial cells [40,41].
In addition to Trx1, other members of the Trx-fold protein
family have been characterized as denitrosylases. Trx-related
protein of 14 kDa (TRP14) is a member of the Trx-fold protein
family which does not act on the same substrates as Trx1
[109]. TRP14 is a highly efficient L-cystine reductase and an
efficient denitrosylase, displaying similar efficiency as Trx1 in
denitrosylating GSNO and s-nitrosylated proteins in
HEK293 cells [110].
Nucleoredoxin (NRX) is another member of the Trx family
which is present in the nucleus and shows the same affinity
for insulin as Trx1 [111]. NRX redox-regulates the Wnt/b-cat-
enin signaling pathway. Over expression of NRX inhibits the
Wnt-b-catenin pathway, whereas down regulation of NRX
expression levels results in activation of the transcription
factor TCF, acceleration of cell proliferation and stimulation of
oncogenic transformation through cooperation with p21Ras
or the protein kinase MEK [112].Thioredoxin-1, S-nitrosylation, tyrosine nitration, and
tumor development
Intracellular SNO levels in normal cells rise upon appropriate
stimuli [85], while abnormally high levels of S-nitrosylated
proteins are found in tumor cells [81,113]. Elevated s-nitrosylation levels have been implicated in tumor progres-
sion [51,81,114,115].
Chronic inflammatory processes are initiating factors in at
least 25% of all cancer cases diagnosed worldwide [116].
Chronic inflammatory processes include high cell counts of
activated macrophages which produce high NO levels derived
from activated iNOS. Elevated levels of s-nitrosylated proteins
are expected in cells exposed chronically to high concentra-
tions of NO. Therefore, carcinogenesis may develop as a result
of abnormal levels of s-nitrosylated proteins that constitute
signaling pathways associated with cancer initiation and
progression [51,81,114,115].
S-nitrosylation of signaling proteins in relation to cancer
progression implies the participation of the NOS isoforms as
intracellular NO sources. The reactivity and abundance of NO
and thiols determine the occurrence of s-nitrosylation at or in
the vicinity of NOS. Formation of a signaling complex
involving the protein target and NOS are essential in guaran-
teeing specificity and temporal regulation of s-nitrosylation
reactions [117]. This nitrosylase heterotrimeric protein com-
plex is composed of iNOS and two other proteins, S100A8 and
S100A9 [118]. The nitrosylase complex conveys NO from iNOS
to specific protein substrates, ensuring specific nitrosylation
of cysteine residues located in an acid-base motif of these
substrates [90]. Signaling events associated with breast cancer
development are directly related to iNOS-mediated s-nitro-
sylation of p21ras, and of the protein tyrosine kinases, EGFR
and Src [84,119].
Elevated expression levels of iNOS are associated with
different types of cancer and their outcome [120,121]. This is
observed in triple negative breast cancer cells from patients
[122] that have high Trx1 expression that is associated with a
poor prognosis [123]. Similar findings are found in the cells of
gastric cancer patients with a poor prognosis, where a positive
correlation between high expression levels of iNOS and Trx1
are associated [101,124].
In addition to specificity, regulation of s-nitrosylation-
mediated signaling pathways involves participation of deni-
trosylases. The Trx system and the GSH/GSNO reductase
system are ubiquitous and physiologically important deni-
trosylases. While the relevance of the GSH/GSNO reductase
system has been previously discussed [42,89], here the
emphasis is on the role of Trx1 in maintaining optimal intra-
cellular SNO levels and cell viability.
Over nitrosylation of proteins is involved in cellular
dysfunction and highly nitrosylated proteins have been
detected in the cells of colon cancer patients [92]. Over nitro-
sylation of neuronal proteins has been associated with the
progression of neurodegenerative diseases [125]. Optimal
physiological levels of S-nitrosylated proteins are essential for
regulating protein activity [85]. Over expression of Trx1 in
cancer cells maintains optimal SNO levels in these cells by up
regulating their survival signaling pathways [126].
The balance between nitrosylation-denitrosylation in cells
may be affected by the expression levels of Txnip. Endoge-
nously generated or exogenously added NO in HeLa cells in-
hibits Txnip expression and facilitates Trx1-mediated
denitrosylation [36]. Over expression of Txnip in human em-
bryonic kidney cells causes an increase in intracellular SNO
levels and promotes cell death [127].
Fig. 3 NO-Trx1 cross talk and the mediation of survival signaling events in the cytoplasm and in the nucleus.
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nitrosylated proteins and in reducing low molecular weight
SNO is needed for the maintenance of intracellular SNO ho-
meostasis. A fine balance involving intracellular SNO homeo-
stasis and nitrosative stress conditions must be kept [42,89].
Elevated Trx1 expression is essential for maintaining the
viability of HeLa cells exposed to pro-apoptotic concentrations
of GSNO. Exposure of wild type HeLa cells to GSNO decreases
Trx1 expression, activates caspase-3, and increases cell death.
Ectopic over-expression of Trx1 in HeLa cells (HeLa-Trx1)
partially attenuates caspase-3 activation and enhances cell
viability upon GSNO treatment. Trx1 denitrosylase activity in
HeLa-Trx1 cells mediates the reduction of intracellular SNO
levels and enhances cell viability. Activation of ERK1/2 MAP
kinases is critical for survival signaling. Basal phosphorylation
levels of ERK1/2MAP kinases in HeLa-Trx1 cells are higher and
further increase after GSNO treatment. This suggests that the
enhanced cell viability promoted by Trx1 correlates with its
capacity to regulate the levels of intracellular SNO and up-
regulate the survival signaling pathway mediated by the
ERK1/2 MAP kinases [37,38]. These findings are similar to
those described in human THP1 monocytes exposed to
nitrosative stress [128].
Formation of secondary products can occur from Trx1-
mediated denitrosylation reactions after the initial step of
trans-nitrosylation. Two reactions may follow trans-
nitrosylation: 1) The S-N bond undergoes a heterolytic
breakdown yielding nitroxyl and hydroxylamines; 2) The S-N
bonds undergoes a homolytic breakdown yielding NO, O2
, and
nitrite [39,43]. A combination of NO and O2
 generates another
reactive species, peroxynitrite (ONOO-), a product of a diffu-
sion controlled reaction between both radical species [129].
ONOO- promotes nitration of tyrosine residues and is an
effective oxidant for thiols and lipids [130]. Increased intra-
cellular tyrosine nitration levels are associated with redox
signaling, nitrative stress, and cytotoxicity [131].
Increased denitrosylase activity in Hela-Trx1 cells is
accompanied by elevation of intracellular nitrotyrosine levels.Elevated nitrotyrosine levels impact on redox regulated
signaling pathways [37]. The redox-associated up regulation
of the ERK1/2 MAP kinases activity is dependent on tyrosine
nitration [132,133]. Nitrotyrosine as a secondary product
derived from Trx1-mediated denitrosylase activity in HeLa-
Trx1 cells up regulates the ERK1/2 MAP kinases through
nitration and/or oxidation of these kinases [37]. Activation of
the ERK1/2 MAP kinases signaling pathway is a critical
mechanism of cell survival. This activation is capable of
delaying or inhibiting cell death [134,135].Conclusion
The intensified research efforts in understanding the NO-Trx1
interplay in cancer development may provide new therapeu-
tic avenues to explore. Regarding the cross talk between NO
and Trx1 in cancer development, control of the intracellular
levels of s-nitrosylated proteins by Trx1-mediated deni-
trosylase activity and the activation of the ERK1/2 MAP ki-
nases signaling pathway are essential for tumor survival.
These signaling events are compartmentalized and occur in
the cytoplasm and in the nucleus in a concerted manner. A
general scheme illustrating the NO-Trx1 interaction in sur-
vival signaling is shown in [Fig. 3].Conflicts of interest
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